๐ฅ๐ฒ๐ฐ๐๐ฟ๐ฟ๐ฒ๐ป๐ ๐ฆ๐๐ฅ๐ฆ-๐๐ผ๐ฉ-2 ๐๐ฝ๐ถ๐ธ๐ฒ ๐บ๐๐๐ฎ๐๐ถ๐ผ๐ป๐ ๐ฐ๐ผ๐ป๐ณ๐ฒ๐ฟ ๐ด๐ฟ๐ผ๐๐๐ต ๐ฎ๐ฑ๐๐ฎ๐ป๐๐ฎ๐ด๐ฒ๐ ๐๐ผ ๐๐ฒ๐น๐ฒ๐ฐ๐ ๐๐ก.1 ๐๐๐ฏ๐น๐ถ๐ป๐ฒ๐ฎ๐ด๐ฒ๐
biorxiv.org/content/10.110โฆ
2) The SARS-CoV-2 Omicron variant JN.1 has evolved into several sublineages containing recurrent spike protein mutations R346T, F456L, and T572I. Some sublineages like KP.2 containing combinations of these mutations have shown growth advantages.
3) This study characterized these mutations individually and in combination using pseudoviruses with the mutated spikes.
Serum neutralization assays found F456L significantly reduced antibody neutralization, while R346T and T572I had little effect.
4) Combinations including F456L were most resistant to antibodies.
F456L impaired neutralization of monoclonal antibodies targeting the RBD class 1 region. T572I modestly reduced SD1-directed antibody neutralization.
5) R346T increased binding affinity to the ACE2 receptor by 1.5-fold and modestly enhanced pseudovirus infectivity. F456L and T572I did not affect receptor binding.
KP.2, which contains R346T, F456L and V1104L, showed similar resistance as JN.1 with R346T and F456L ...
6) ...suggesting V1104L does not impact antibody evasion.
The study characterized how these recurrent mutations confer advantages like antibody evasion and receptor binding that help explain the expansion of lineages containing them, informing vaccine booster design.
Thanks๐
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.